TY - JOUR
T1 - Analysis of immune reconstitution after autologous CD34 + stem/progenitor cell transplantation for systemic sclerosis
T2 - Predominant reconstitution of Th1 CD4 + t cells
AU - Tsukamoto, Hiroshi
AU - Nagafuji, Koji
AU - Horiuchi, Takahiko
AU - Mitoma, Hiroki
AU - Niiro, Hiroaki
AU - Arinobu, Yojiro
AU - Inoue, Yasushi
AU - To, Kentaro
AU - Miyamoto, Toshihiro
AU - Iwasaki, Hiromi
AU - Teshima, Takanori
AU - Harada, Mine
AU - Akashi, Koichi
N1 - Funding Information:
Funding: This work was supported in part by grants from the Ministry of Health, Labor and Welfare (H22-Immunity-Ippan-008) and from the Ministry of Education, Science, Sports and Culture of Japan (21591266).
PY - 2011/5
Y1 - 2011/5
N2 - Objective: The aim of this study is to evaluate the mechanism of long-term effect of autologous haematopoietic stem cell transplantation (ASCT) in treatment of SSc. Methods: Eleven patients (three males and eight females) with SSc were enrolled. Blood mononuclear cells were harvested after mobilization treatment with CYC and G-CSF. CD34 + haematopoietic stem/progenitor cell fractions were purified and cryopreserved. Patients were transplanted with >2 × 10/kg autologous CD34 + cells after high-dose CYC (50 mg/kg for 4 days) conditioning. Immune reconstitution was evaluated serially by analysing lymphocyte subpopulations for 36 months. Results: Progressive improvement of skin sclerosis has been observed for 3 years in most of the patients. The serum level of anti-Scl-70, an auto-antibody specific to SSc, was progressively decreased after ASCT. Improvement of skin sclerosis was significantly associated with the change in the serum anti-Scl-70 level after ASCT at 36 months. Serum levels of KL-6 and surfactant protein D, indicators for interstitial pneumonia activity, were also significantly decreased. The number of CD8+ T cells immediately recovered within a month after ASCT, while the number of CD4+ T cells remained low for >36 months post-transplant. The majority of CD4 + cells were memory but not naïve T cells, and regulatory CD4 + T cells were not recovered. Th1/Th2 ratio was significantly increased after ASCT. Conclusions: ASCT with purified CD34 + cells was effective in controlling the disease activity of SSc. Th1/Th2 ratio was significantly increased for at least 3 years after ASCT.
AB - Objective: The aim of this study is to evaluate the mechanism of long-term effect of autologous haematopoietic stem cell transplantation (ASCT) in treatment of SSc. Methods: Eleven patients (three males and eight females) with SSc were enrolled. Blood mononuclear cells were harvested after mobilization treatment with CYC and G-CSF. CD34 + haematopoietic stem/progenitor cell fractions were purified and cryopreserved. Patients were transplanted with >2 × 10/kg autologous CD34 + cells after high-dose CYC (50 mg/kg for 4 days) conditioning. Immune reconstitution was evaluated serially by analysing lymphocyte subpopulations for 36 months. Results: Progressive improvement of skin sclerosis has been observed for 3 years in most of the patients. The serum level of anti-Scl-70, an auto-antibody specific to SSc, was progressively decreased after ASCT. Improvement of skin sclerosis was significantly associated with the change in the serum anti-Scl-70 level after ASCT at 36 months. Serum levels of KL-6 and surfactant protein D, indicators for interstitial pneumonia activity, were also significantly decreased. The number of CD8+ T cells immediately recovered within a month after ASCT, while the number of CD4+ T cells remained low for >36 months post-transplant. The majority of CD4 + cells were memory but not naïve T cells, and regulatory CD4 + T cells were not recovered. Th1/Th2 ratio was significantly increased after ASCT. Conclusions: ASCT with purified CD34 + cells was effective in controlling the disease activity of SSc. Th1/Th2 ratio was significantly increased for at least 3 years after ASCT.
UR - http://www.scopus.com/inward/record.url?scp=79955133066&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79955133066&partnerID=8YFLogxK
U2 - 10.1093/rheumatology/keq414
DO - 10.1093/rheumatology/keq414
M3 - Article
C2 - 21172925
AN - SCOPUS:79955133066
SN - 1462-0324
VL - 50
SP - 944
EP - 952
JO - Rheumatology
JF - Rheumatology
IS - 5
M1 - keq414
ER -